HY1272 + osimertinib

**HY1272 + osimertinib** is a combination regimen under investigation for the treatment of locally advanced or metastatic solid tumors, including EGFR mutation-positive non-small cell lung cancer (NSCLC). HY1272 is an investigational agent administered intravenously, while osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Osimertinib targets sensitizing and resistance EGFR mutations to block downstream signaling and tumor growth, sparing wild-type EGFR. The combination is being evaluated for its safety, tolerability, pharmacokinetics, and antitumor activity, with a focus on whether the combined blockade of EGFR and the as-yet-unknown target of HY1272 can improve outcomes over EGFR inhibition alone[1][2].